High prevalence of bevirimat resistance mutations in protease inhibitor-resistant HIV isolates

AIDS

Volumn 24, Issue 5, 2010, Pages 669-673

  Verheyen, Jens ^a   Verhofstede, Chris ^b   Knops, Elena ^a   Vandekerckhove, Linos ^b   Fun, Axel ^c   Brunen, Diede ^c   Dauwe, Kenny ^b   Wensing, Annemarie M J ^c   Pfister, Herbert ^a   Kaiser, Rolf ^a   Nijhuis, Monique ^c  

^a UNIVERSITY OF COLOGNE   (Germany)

^b GHENT UNIVERSITY   (Belgium)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Bevirimat; Cleavage sites; Gag p2; Protease inhibitor resistance

Indexed keywords

ALANINE; AMINO ACID; BEVIRIMAT; CYSTEINE; GAG PROTEIN; GLUTAMINE; HISTIDINE; LEUCINE; METHIONINE; PROLINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SERINE; THREONINE; TYROSINE; VALINE;

AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; EUROPE; GENE DELETION; GENE MUTATION; GENE SEQUENCE; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT FAILURE; VIRUS DETECTION; VIRUS ISOLATION; VIRUS STRAIN;

DRUG RESISTANCE, VIRAL; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENOTYPE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; PREVALENCE; SEQUENCE ANALYSIS, DNA; SUCCINATES; TRITERPENES;

EID: 77949404674     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32833160fa     Document Type: Article

References (27)

1. Chiao SK, Romero DL, Johnson DE. Current HIV therapeutics: mechanistic and chemical determinants of toxicity. Curr Opin Drug Discov Devel 2009; 12:53-60.
2. Aberg JA. Cardiovascular complications in HIV management: past, present, and future. J Acquir Immune Defic Syndr 2009; 50:54-64.
3. ZhouJ,HuangL,HacheyDL,ChenCH,AikenC.InhibitionofHIV-1 maturation via drug association with the viral gag protein in immature HIV-1 particles. J Biol Chem 2005; 280:42149-42155.
4. Zhou J, Yuan X, Dismuke D, Forshey BM, Lundquist C, Lee KH, et al. Small-molecule inhibition of human immunodeficiency virus type 1 replication by specific targeting of the final step of virion maturation. J Virol 2004; 78:922-929.
5. Li F, Zoumplis D, Matallana C, Kilgore NR, Reddick M, Yunus AS, et al. Determinants of activity of the HIV-1 maturation inhibitor PA-457. Virology 2006; 356:217-224.
6. Salzwedel K, Reddick M, Matallana C, Finnegan C, Adamson C, SakalianM, et al. Role of gag polymorphisms in HIV-1 sensitivity to the maturation inhibitor bevirimat. In: XVII International HIV Drug Resistance Workshop; 10-14 June 2008; Sitges, Spain.
7. Zhou J, Chen CH, Aiken C. Human immunodeficiency virus type 1 resistance to the small molecule maturation inhibitor 3-O-(3,3-dimethylsuccinyl)-betulinic acid is conferred by a variety of single amino acid substitutions at the CA-SP1 cleavage site in Gag. J Virol 2006; 80:12095-12101.
8. Salzwedel K, Martin DE, Sakalian M. Maturation inhibitors: a new therapeutic class targets the virus structure. AIDS Rev 2007; 9:162-172.
9. Smith PF, Ogundele A, Forrest A, Wilton J, Salzwedel K, Doto J, et al. Phase I and II study of the safety, virologic effect, and pharmacokinetics/ pharmacodynamics of single-dose 3-o-(3,3-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection. Antimicrob Agents Chemother 2007; 51:3574-3581.
10. Adamson CS, Ablan SD, Boeras I, Goila-Gaur R, Soheilian F, Nagashima K, et al. In vitro resistance to the human immunodeficiency virus type 1 maturation inhibitor PA-457 (Beviri-mat). J Virol 2006; 80:10957-10971.
11. McCallister S, Lalezari J, Richmond G, Thompson M, Harrigan R, Martin D, et al. HIV-1 gag polymorphisms determine treatment response to bevirimat (PA-457). In: XVII International HIV Drug Resistance Workshop; 10-14 June 2008; Sitges, Spain.
12. Salzwedel K, Hamy F, Louvel S, Sakalian M, Reddick M, Finnegan C, et al. Susceptibility of diverse HIV-1 patient isolates to the maturation inhibitor, bevirimat, is determined by clade-specific polymorphisms in gag CA-SP1. In: 16th Conference on Retroviruses and Opportunistic Infections; 8-11 February 2009; Montreal, Quebec.
13. Malet I, Wirden M, Derache A, Simon A, Katlama C, Calvez V, Marcelin AG. Primary genotypic resistance of HIV-1 to the maturation inhibitor PA-457 in protease inhibitor-experienced patients. AIDS 2007; 21:871-873.
14. Verheyen J, Knops E, Kupfer B, Hamouda O, Somogyi S, Schuldenzucker U, et al. Prevalence of C-terminal gag cleavage site mutations in HIV from therapy-naive patients. J Infect 2009; 58:61-67.
15. Verheyen J, Litau E, Sing T, Daumer M, Balduin M, Oette M, et al. Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6-gag in therapy-naive and therapy-experienced patients. Antivir Ther 2006; 11:879-887.
16. Shafer RW, Rhee SY, Pillay D, Miller V, Sandstrom P, Schapiro JM, et al. HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS 2007; 21:215-223.
17. Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, et al. Update of the drug resistance mutations in HIV-1. Top HIV Med 2008; 16:138-145.
18. van Maarseveen NM, de Jong D, Boucher CA, Nijhuis M. An increase in viral replicative capacity drives the evolution of protease inhibitor-resistant human immunodeficiency virus type 1 in the absence of drugs. J Acquir Immune Defic Syndr 2006; 42:162-168.
19. Steegen K, Demecheleer E, De Cabooter N, Nges D, Temmer-man M, Ndumbe P, et al. A sensitive in-house RT-PCR genotyp-ing system for combined detection of plasma HIV-1 and assessment of drug resistance. J Virol Methods 2006; 133:137-145.
20. Oette M, Kaiser R, Daumer M, Petch R, Fatkenheuer G, Carls H, et al. Primary HIV drug resistance and efficacy of first-line antiretroviral therapy guided by resistance testing. J Acquir Immune Defic Syndr 2006; 41:573-581.
21. Van Baelen K, SalzwedelK,RondelezE, Van EygenV, DeVos S, Verheyen A, et al. Susceptibility of human immunodeficiency virus type 1 to the maturation inhibitor bevirimat is modulated by baseline polymorphisms in Gag spacer peptide 1. Antimi-crob Agents Chemother 2009; 53:2185-2188.
22. Nijhuis M, van Maarseveen NM, Lastere S, Schipper P, Coakley E, Glass B, et al. A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism. PLoS Med 2007; 4:e36.
23. Nijhuis M, van Maarseveen NM, Verheyen J, Boucher CAB. Novel mechanisms of HIV protease inhibitor resistance. Curr Opin HIV AIDS 2008; 3:627-632.
24. Malet I, Roquebert B, Dalban C, Wirden M, Amellal B, Agher R, et al. Association of gag cleavage sites to protease mutations and to virological response in HIV-1 treated patients. J Infect 2007; 54:367-374.
25. Knapp DJHF, Huang S, Harrigan PR. Stable prevalence of bevirimat-related HIV gag polymorphisms both before and after HAART exposure. In: 16th Conference on Retroviruses and Opportunistic Infections; 8-11 February 2009; Montreal, Quebec.
26. Van Baelen K, Salzwedel K, De Wolf H, Verlinden Y, Stuyver LJ. HIV-1 susceptibility to the maturation inhibitor bevirimat is modulated by natural polymorphisms at positions 369-371 in Gag spacer peptide 1. In: XVII International HIV Drug Resistance Workshop; 10-14 June 2008; Sitges, Spain.
27. Margot NA, Gibbs CS, Miller MD. Phenotypic susceptibility to bevirimat among HIV-infected patient isolates without prior exposure to bevirimat. In: 16th Conference on Retroviruses and Opportunistic Infections; 8-11 February 2009; Montreal, Quebec.